
Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic
pharmafile | March 12, 2018 | News story | Sales and Marketing | Impax, Medicis, Solodyn, Valeant, generic, pharma
Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it is facing related to allegations that it entered into an agreement to delay its own generic version of Valeant’s acne medication Solodyn from hitting the market.
According to the allegations, Impax accepted $40 million and $23 million in milestone payments from Valeant-owned Medicis back in 2008 after it agreed not to pursue an appeal to a court ruling on a lawsuit to invalidate a Solodyn patent. The company did not begin to market its generic version of the drug until 2011, despite securing FDA approval in 2009.
While it agreed to the payment, Impax did not admit liability. Consumers and insurers have reportedly been overcharged to the tune of $790.3 million as a result of the deal.
Valeant itself agreed to pay $58 million in February to resolve a class action lawsuit concerning Solodyn, a drug it acquired when it bought out Medicis Pharmaceutical in 2012.
Matt Fellows
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






